Journal article
Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report)
Abstract
PurposeRecombinant activated factor VII (rFVIIa) is a pro-hemostatic drug that is approved for treatment of bleeding in hemophilia patients, but it is frequently used off-label in non-hemophiliacs. The purpose of this study was to determine if the off-label use of rFVIIa is expanding and whether this poses a net harm to patients.MethodsFor this historical cohort study, data were collected on all non-hemophilia patients who received rFVIIa from …
Authors
Karkouti K; Arellano R; Aye T; Dupuis J-Y; Kent B; Lee TWR; Lin Y; Ralley F; MacAdams C; Mazer CD
Journal
Journal canadien d'anesthésie, Vol. 61, No. 8, pp. 727–735
Publisher
Springer Nature
Publication Date
August 2014
DOI
10.1007/s12630-014-0184-z
ISSN
0832-610X